Combination use of anti-CD133 antibody and SSA lectin can effectively enrich cells with high tumorigenicity

Cancer Science

Volumn 102, Issue 6, 2011, Pages 1164-1170

  Moriwaki, Kenta ^a   Okudo, Kumiko ^a   Haraguchi, Naotsugu ^b   Takeishi, Shunsaku ^c   Sawaki, Hiromichi ^d   Narimatsu, Hisashi ^d   Tanemura, Masahiro ^b   Ishii, Hideshi ^b   Mori, Masaki ^b   Miyoshi, Eiji ^a  

^a Departments of Molecular Biochemistry and Clinical Investigation   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c GP Biosciences Ltd   (Japan)

^d NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; GLYCAN; LECTIN; LECTIN ABA; LECTIN ACG; LECTIN MAH; LECTIN MAL I; LECTIN SNA; LECTIN SSA; LECTIN TJA I; MICROSOMAL AMINOPEPTIDASE; SIALOGLYCOPROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CANCER STEM CELL; CARCINOGENICITY; CELL ISOLATION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE;

ANIMALS; ANTIBODIES; ANTIGENS, CD; ANTIGENS, CD13; CELL SEPARATION; FLOW CYTOMETRY; GLYCOPROTEINS; LECTINS; MICE; MICE, INBRED NOD; MICE, SCID; MICROARRAY ANALYSIS; NEOPLASTIC STEM CELLS; PEPTIDES; POLYMERASE CHAIN REACTION; POLYSACCHARIDES; TUMOR MARKERS, BIOLOGICAL;

EID: 79956209666     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.01923.x     Document Type: Article

References (46)

1. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-11.
2. Ailles LE, Weissman IL. Cancer stem cells in solid tumors. Curr Opin Biotechnol 2007; 18: 460-6.
3. Clarke MF, Dick JE, Dirks PB et al. Cancer stem cells - perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 2006; 66: 9339-44.
4. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5: 275-84.
5. Bao S, Wu Q, McLendon RE et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-60.
6. Lapidot T, Sirard C, Vormoor J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-8.
7. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100: 3983-8.
8. Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
9. Galli R, Binda E, Orfanelli U et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004; 64: 7011-21.
10. Patrawala L, Calhoun T, Schneider-Broussard R et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006; 25: 1696-708.
11. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-10.
12. Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445: 111-5.
13. Dalerba P, Dylla SJ, Park IK et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 2007; 104: 10158-63.
14. Li C, Heidt DG, Dalerba P et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-7.
15. Wu Y, Wu PY. CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev 2009; 18: 1127-34.
16. Haraguchi N, Ohkuma M, Sakashita H et al. CD133+CD44+ population efficiently enriches colon cancer initiating cells. Ann Surg Oncol 2008; 15: 2927-33.
17. Haraguchi N, Ishii H, Mimori K et al. CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest 2010; 120: 3326-39.
18. Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 2005; 5: 526-42.
19. Haltiwanger RS, Lowe JB. Role of glycosylation in development. Annu Rev Biochem 2004; 73: 491-537.
20. Solter D, Knowles BB. Monoclonal antibody defining a stage-specific mouse embryonic antigen (SSEA-1). Proc Natl Acad Sci U S A 1978; 75: 5565-9.
21. Muramatsu T, Muramatsu H. Carbohydrate antigens expressed on stem cells and early embryonic cells. Glycoconj J 2004; 21: 41-5.
22. Varki A. Sialic acids in human health and disease. Trends Mol Med 2008; 14: 351-60.
23. Yogeeswaran G, Salk PL. Metastatic potential is positively correlated with cell surface sialylation of cultured murine tumor cell lines. Science 1981; 212: 1514-6.
24. Fogel M, Altevogt P, Schirrmacher V. Metastatic potential severely altered by changes in tumor cell adhesiveness and cell-surface sialylation. J Exp Med 1983; 157: 371-6.
25. Passaniti A, Hart GW. Cell surface sialylation and tumor metastasis. Metastatic potential of B16 melanoma variants correlates with their relative numbers of specific penultimate oligosaccharide structures. J Biol Chem 1988; 263: 7591-603.
26. Kuno A, Uchiyama N, Koseki-Kuno S et al. Evanescent-field fluorescence-assisted lectin microarray: a new strategy for glycan profiling. Nat Methods 2005; 2: 851-6.
27. Ito H, Kuno A, Sawaki H et al. Strategy for glycoproteomics: identification of glyco-alteration using multiple glycan profiling tools. J Proteome Res 2009; 8: 1358-67.
28. Narimatsu H, Sawaki H, Kuno A, Kaji H, Ito H, Ikehara Y. A strategy for discovery of cancer glyco-biomarkers in serum using newly developed technologies for glycoproteomics. FEBS J 2010; 277: 95-105.
29. Ikehara Y, Kojima N, Kurosawa N et al. Cloning and expression of a human gene encoding an N-acetylgalactosamine-alpha2, 6-sialyltransferase (ST6GalNAc I): a candidate for synthesis of cancer-associated sialyl-Tn antigens. Glycobiology 1999; 9: 1213-24.
30. Ma XC, Terata N, Kodama M, Jancic S, Hosokawa Y, Hattori T. Expression of sialyl-Tn antigen is correlated with survival time of patients with gastric carcinomas. Eur J Cancer 1993; 29A: 1820-3.
31. Werther JL, Rivera-MacMurray S, Bruckner H, Tatematsu M, Itzkowitz SH. Mucin-associated sialosyl-Tn antigen expression in gastric cancer correlates with an adverse outcome. Br J Cancer 1994; 69: 613-6.
32. Werther JL, Tatematsu M, Klein R et al. Sialosyl-Tn antigen as a marker of gastric cancer progression: an international study. Int J Cancer 1996; 69: 193-9.
33. Soares R, Marinho A, Schmitt F. Expression of sialyl-Tn in breast cancer. Correlation with prognostic parameters. Pathol Res Pract 1996; 192: 1181-6.
34. Kinney AY, Sahin A, Vernon SW et al. The prognostic significance of sialyl-Tn antigen in women treated with breast carcinoma treated with adjuvant chemotherapy. Cancer 1997; 80: 2240-9.
35. Kobayashi H, Terao T, Kawashima Y. Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer. J Clin Oncol 1992; 10: 95-101.
36. Noda K, Miyoshi E, Gu J et al. Relationship between elevated FX expression and increased production of GDP-L-fucose, a common donor substrate for fucosylation in human hepatocellular carcinoma and hepatoma cell lines. Cancer Res 2003; 63: 6282-9.
37. Moriwaki K, Noda K, Nakagawa T et al. A high expression of GDP-fucose transporter in hepatocellular carcinoma is a key factor for increases in fucosylation. Glycobiology 2007; 17: 1311-20.
38. Satomaa T, Heiskanen A, Mikkola M et al. The N-glycome of human embryonic stem cells. BMC Cell Biol 2009; 10: 42.
39. - progenitor cells. Blood 1991; 77: 1218-27.
40. Choo AB, Tan HL, Ang SN et al. Selection against undifferentiated human embryonic stem cells by a cytotoxic antibody recognizing podocalyxin-like protein-1. Stem Cells 2008; 26: 1454-63.
41. Hara T, Nakano Y, Tanaka M et al. Identification of podocalyxin-like protein 1 as a novel cell surface marker for hemangioblasts in the murine aorta-gonad-mesonephros region. Immunity 1999; 11: 567-78.
42. Yamashita T, Ji J, Budhu A et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009; 136: 1012-24.
43. Zhu Z, Hao X, Yan M et al. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer 2010; 126: 2067-78.
44. Chiba T, Miyagi S, Saraya A et al. The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. Cancer Res 2008; 68: 7742-9.
45. Yi SY, Nan KJ. Tumor-initiating stem cells in liver cancer. Cancer Biol Ther 2008; 7: 325-30.
46. Sasaki N, Moriwaki K, Uozumi N et al. High levels of E4-PHA-reactive oligosaccharides: potential as marker for cells with characteristics of hepatic progenitor cells. Glycoconj J 2009; 26: 1213-23.